此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

前列腺癌、遗传风险和公平筛查研究 (ProGRESS) (ProGRESS)

2026年11月10日 更新者:VA Office of Research and Development

前列腺癌、遗传风险和公平筛查研究 (ProGRESS):精准前列腺癌筛查的实用试验

Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.

研究概览

详细说明

Prostate cancer is the most common non-cutaneous cancer in US men and in the Veterans Health Administration (VHA): 1 in 8 will be diagnosed with the disease in their lifetime. Many cases are non-lethal, but prostate cancer remains the 2nd leading cause of cancer death among US men, representing 2.5% of all deaths. VHA diagnoses >16,000 new cases annually and cares for >400,000 men living with prostate cancer. As a result, prostate cancer diagnosis and treatment is a national priority for VHA.

A major impediment to reducing the incidence of metastatic prostate cancer and prostate cancer death is the lack of an optimal screening strategy to identify men at high risk. Screening with prostate-specific antigen (PSA) testing modestly reduces prostate cancer deaths but at the cost of overdiagnoses and overtreatment. Current screening approaches do not adequately distinguish men without prostate cancer or with low-grade prostate cancer amenable to active surveillance from men with clinically significant prostate cancer, who need treatment. As a result, clinical guidelines do not recommend universal prostate cancer screening, including those from the United States Preventive Services Task Force (USPSTF) and the VHA National Center for Health Promotion and Disease Prevention. Still, many men undergo screening based on variable and subjective assessments of their race/ethnicity, family history, and other risk factors.

A new paradigm of precision screening could improve the benefit-to-harm ratio of screening by implementing screening strategies tailored to an individual's specific genetic profile. Due to advances in high-throughput genotyping and sequencing, increasingly large and diverse cohort studies, and standardization of genetic variant classification, germline genetic testing is emerging as a powerful predictor for prostate cancer, including metastatic and lethal disease. This includes both rare highly penetrant variants and polygenic risk scores (PRS), which characterize an individual's predisposition to prostate cancer due to common genetic variation. Rare and common genetic variation is now an equally powerful predictor of clinically significant disease as self-reported race or family history, including in the Million Veteran Program.

This clinical trial will evaluate the promise of precision risk stratification to identify men most likely to benefit from prostate cancer screening. During the proof-of-concept phase, the investigators will achieve the following aims:

  1. Develop a precision prostate cancer screening intervention consisting of genetic testing for rare variants and a transancestry PRS, delivered to participants and their primary care providers along with individualized, genetic risk-informed screening recommendations.
  2. Determine the feasibility of enrolling men aged 55-70 ( 35% of whom are of racial/ethnic minority groups) to a pragmatic randomized clinical trial (RCT) comparing the precision screening intervention to usual care.
  3. Perform an interim assessment to determine whether the observed trajectory of negative prostate biopsy event rates is consistent with rates needed to detect a meaningful between-group difference at the end of the 7-year project period.

Following demonstration of enrollment feasibility and observation of adequate event rates during the proof-of-concept phase, the RCT will continue to the clinical trial phase to test the following co-primary hypotheses:

  1. Compared with men in the usual care arm, men in the precision screening arm will have a higher incidence rate of clinically significant prostate cancer (csPCa, defined as NCCN classification intermediate risk or higher) detection over the trial follow-up period.
  2. Compared with men in the usual care arm, men in the precision screening arm will have a lower incidence rate of negative prostate biopsies over the trial follow-up period.

Pre-specified subgroup analyses will test these hypotheses in Black men specifically, to evaluate whether this population benefits equally or more from the intervention. Enrollees will be followed for additional outcomes including all prostate cancer diagnoses, PSA testing, prostate MRI, rare variants identified, preferences for or against prostate cancer screening, and health-related quality of life.

The investigators expect that precision screening will increase screening among high-risk patients but decrease screening among low- and average-risk patients, thereby maintaining or improving overall csPCa detection while improving the population-level benefit-to-harm ratio. Rigorous RCT evidence that genetic risk-informed screening maintains the benefits of screening while minimizing the harms of unnecessary procedures and treatments among low-risk men will change clinical practice and policy around prostate cancer screening.

研究类型

介入性

注册 (估计的)

5000

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02130-4817
        • 招聘中
        • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
        • 接触:
        • 首席研究员:
          • Jason L Vassy, MD MPH

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

55年 至 69年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • baseline age 55-69 years
  • receipt of regular VA care
  • Veteran status

Exclusion Criteria:

  • personal history of prostate cancer
  • prior prostate biopsy, prostatectomy, or prostate MRI
  • known carrier status of rare variant associated with cancer syndrome

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:放映
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Precision screening intervention

The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

实验性的:Usual care

Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Diagnosis of clinically significant prostate cancer
大体时间:7 years

Cases of csPCa will be abstracted from VA and survey data and defined using NCCN classifications of intermediate risk or higher: PSA 10 and/or Grade Group 2 and/or clinical T stage T2b

7 years
Negative prostate biopsy
大体时间:7 years

Counts of negative prostate biopsies not temporally associated with csPCa (within 6 months of diagnosis) will be abstracted from VA and survey data

7 years

次要结果测量

结果测量
措施说明
大体时间
Diagnosis of prostate cancer
大体时间:7 years

All cases of prostate cancer will be abstracted from VA and survey data

7 years
Prostate biopsy
大体时间:7 years

Counts of all prostate biopsies will be abstracted from VA and survey data.

7 years
PSA testing
大体时间:7 years

PSA testing will be identified from VA and survey data

7 years
Prostate MRI
大体时间:7 years

Prostate magnetic resonance imaging will be identified from VA and survey data

7 years
Self-rated health
大体时间:7 years

Self-rated health will be collected at the baseline survey and every 6 months with a single-item self-rating of health on a Likert scale from "poor" to "excellent.

7 years
Quality of life
大体时间:5 years

Health-related quality of life is collected through the Veterans RAND 12-Item Health Survey (VR-12) on the baseline survey and at each participant's 5-year survey or last survey

5 years

其他结果措施

结果测量
措施说明
大体时间
Adherence to precision cancer screening recommendations
大体时间:7 years

The precision screening intervention will include the recommendation that high-risk men undergo PSA screening and that low-risk men not undergo screening. The investigators will define adherence to the intervention in these two groups of men as the presence and absence of PSA testing, respectively, during the observation period.

7 years
Acceptability of the precision prostate cancer screening intervention
大体时间:7 years

The survey will assess patient acceptability of the precision screening with a 3-item instrument assessing patient perspective on the 1) amount of information presented, 2) length of the information, 3) clarity of the information, with each domain scored on a 5-point Likert scale.

7 years
Rare pathogenic/likely pathogenic variants
大体时间:7 years

Proportion of participants with a rare P/LP variant associated with hereditary prostate cancer

7 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jason L Vassy, MD MPH、VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年2月1日

初级完成 (估计的)

2029年9月30日

研究完成 (估计的)

2030年9月30日

研究注册日期

首次提交

2023年6月21日

首先提交符合 QC 标准的

2023年6月21日

首次发布 (实际的)

2023年7月3日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Individual participant data will be stored in a data repository available for request by approved individuals.

IPD 共享访问标准

Requestors may be required to have IRB approval, data use agreements, and other regulatory and administrative credentials and authorizations prior to receiving data.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 分析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅